Probiotics for monogastrics: worth the inclusion?

Most of us learned early that bacteria are something to guard against. But what about the friendly kind, and specifically, what can they do inside the gut of a pig or a broiler?

Probiotics, the "good" bacteria, have gone from a niche idea to one of the most talked-about additive categories in monogastric nutrition. Part of that is fashion. But a large part is regulatory necessity. For decades, antibiotic growth promoters (AGPs) were a routine tool for lifting performance and holding gut health steady. The EU banned them as growth promoters back in January 2006, under Regulation (EC) No 1831/2003, with antimicrobial resistance squarely in its sights¹. That withdrawal, followed more recently by the ban on therapeutic zinc oxide (ZnO) for piglets, has left a real gap, and probiotics are among the leading candidates to fill it.

I've spent a good part of the last decade around feed additives, and few categories generate as much noise, or as much genuine confusion as this one. So let's take it slowly: what probiotics actually are, how they're thought to work, and what the latest and most robust research says about whether they earn their place in your formulas.

As with a lot of nutritional concepts, the simplified version on the label doesn't tell the whole story. Probiotics are usually defined as live microorganisms that, fed at an adequate dose, confer a health benefit on the host. In monogastric nutrition, two genera dominate the research. The first is Lactobacillus, one of the lactic acid bacteria (LAB), which ferment carbohydrates into lactic acid and lower gut pH. The second is Bacillus, which are spore forming. That last point matters more than it looks, and we'll come back to it.

Probiotics have a counterpart: prebiotics. These are non-digestible ingredients that selectively feed the beneficial bacteria already living in the gut. The simplest way to picture it is fuel and engine, with prebiotics as the fuel. Combine the two on purpose and you get a synbiotic, the idea being that the fibre helps the introduced bacteria settle in and do their job. It's worth keeping the three straight in your head, because a lot of product labelling quietly blurs them together.

The gut is a crowded place, and a healthy tract holds a large, reasonably stable bacterial population. But that balance is fragile, and weaning, as you know better than most, is about as much upheaval as a young gut ever sees.

Probiotics are thought to tip the balance back the host's way through several overlapping mechanisms¹. They compete with pathogens for nutrients and for space on the gut wall. They produce antimicrobial compounds, bacteriocins and organic acids among them, and lower the local pH to make life difficult for the bad guys. They shore up the intestinal barrier by promoting the tight junction proteins, occludin and ZO-1, that seal the gut lining: the difference, in effect, between a sealed wall and a leaky one. And they nudge the immune response, including the secretory IgA that acts as a first line of defence at the mucosal surface¹.

Here's the catch, and it's the single most important thing to hold onto: no strain does all of these equally well. The effect of a probiotic is strain-specific, and I can't stress this enough. A Bacillus subtilis and a Lactobacillus acidophilus are not doing the same job. And even two strains of the same species can behave completely differently. One might actively neutralise a nasty E. coli challenge; its near-identical twin might do nothing but take up space and enjoy the free ride. The old dog-breeds line captures it well: they're all dogs, but a Border Collie and a Chihuahua have very different temperaments and jobs. Treating "probiotic" as one interchangeable thing is the first mistake to avoid.

Dose matters too, though not as simply as you might expect. There's little evidence of benefit below around 10⁸ colony forming units (CFU) per day. But above the threshold a given strain needs, more is not automatically better, and the research below shows exactly that.

Viability is the other half of the story, and this is one where the practical side of feed manufacturing really bites. Probiotics are sensitive, in a strain-dependent way, to the heat, moisture and acidity they meet on the way through a mill and a gut. Bacillus has a real structural edge here. As a spore former, it shrugs off pelleting temperatures and gut acidity and stores for long periods without losing viability, because the spore is a dormant, armoured form that only wakes up once it's inside the animal². A lactic acid bacterium, with no such armour, is far more exposed to the same conditions². File that away, because it turns up in the data further down.

Here's the honest picture. Plenty of trials show clear performance benefits. Plenty of others show none at all. That isn't a problem with the concept. It's the fingerprint of heterogeneity: different strains, at different doses, in different breeds, on different diets, for different durations, under different levels of health challenge. Any single trial, however clean, tells you very little on its own about what will happen in your barn.

When science hits this kind of noise, the standard move is a meta-analysis: pool all the previous trials on a question and use statistics to reach a more robust conclusion than any single study could. For monogastric probiotics, a strong one landed in 2026, and it's worth walking through, because how it was built is as revealing as what it found.

Published in Poultry Science by a team at McGill University, the study set out to pin down the real effect of probiotics on broiler growth, and to work out what changes that effect³. The authors declared no competing financial interests, which for a category this commercially loaded is worth noting.

Following PRISMA guidelines, the standard framework for a rigorous systematic review, they pulled in 53 studies covering 106 independent trials. They pooled the results with random-effects models, measured the scatter between studies with formal heterogeneity statistics, and, importantly, didn't stop at a single headline number. Through subgroup analysis they tested which factors actually moved feed conversion ratio (FCR): probiotic genus, dose, trial duration, breed, feed type, even the economic status of the region where each trial was run. They also checked for publication bias and corrected for it, a way of estimating whether the less flattering results had quietly gone unpublished.

The headline was positive. Across all trials, probiotic supplementation significantly improved body weight, by 66.6 g, along with feed intake (around 30 g) and FCR (0.058 points). And after correcting for publication bias, those estimates grew rather than shrank, the body-weight gain rising to 78.3 g³. So at the level of the pooled average, probiotics earn their keep in broilers.

But the useful findings sit in the detail. First, genus decided durability. Bacillus-based probiotics improved FCR consistently across the whole cycle, at days 21, 35 and 42. Lactobacillus effects were transient: there at day 21, gone soon after³. So genus determined not just whether there was a benefit, but whether it lasted to slaughter. Remember that structural advantage of the spore, the one I asked you to file away? Here it is, showing up in the numbers.

The second finding is the one I'd carry into any decision. The benefit was significantly larger in trials from developing regions, where baseline hygiene, health pressure and diet quality tend to be lower³. Put plainly: a strain that shines in a high-challenge setting may do far less in a clean, well-run European unit already close to its genetic ceiling. How much room there is to improve is itself part of the result.

The authors' own summing-up is blunt: the findings, they write, "enhance broiler performance, with Bacillus providing superior and sustained efficacy." In plain English: probiotics reliably help broilers on average, but the size of that help is set by genus and by how much challenge the birds are under. And if durability to slaughter is what you care about, Bacillus is the safer bet.

One point the authors make themselves is worth carrying with you. Even with a positive pooled effect, the variation between studies stayed high and their moderators explained only a modest slice of it; the prediction interval for future trials was wide enough to reach effects close to zero. The average is real, in other words, but any single unit can still land almost anywhere along it, which is exactly why the pooled number is a starting point, not a promise.

Set against that uncertainty, one reassurance. When the analysts corrected for the studies that likely never made it into print, every estimate moved up rather than down, a sign the average benefit is real and not just an artefact of selective reporting.

Pooled averages point you in the right direction. But a single, well-run trial shows you how the effect actually behaves, limits and all. One from the University of Guelph is especially instructive⁴.

The researchers had a very practical question in mind, and it's one I suspect a lot of you have asked lately. With therapeutic zinc oxide on its way out, could a Bacillus subtilis probiotic stand in for it in newly weaned pigs, and if so, at what dose? They took 96 nursery pigs and split them into four groups: a negative control on the basal diet, a positive control on pharmacological zinc oxide, and two probiotic groups fed the same B. subtilis strain at very different levels, a low dose at 2 × 10⁷ CFU per pig and a high dose a hundred times stronger at 2 × 10⁹. Then they tracked growth, diarrhoea, the bacterial populations in the faeces, and the expression of genes controlling the gut barrier and inflammation.

The results are a lesson in reading past the headline. On the bluntest measure, bodyweight, the probiotic did not beat the control. A quick glance would file it under "failure" and move on. But that glance would miss almost everything worth seeing. Both doses lowered FCR and cut diarrhoea to a level on par with zinc oxide. Both reduced faecal E. coli and coliforms while raising beneficial lactic acid bacteria. And at the gut wall itself, the probiotic groups showed less of the inflammatory signal IL-8 and more of the tight junction proteins occludin and TJP-1 (the same protein sometimes labelled ZO-1 further up), plus the mucin MUC-1: all signs of a better-sealed, healthier barrier⁴. So the strain was doing real, measurable work on gut health and pathogen control, matching pharmacological zinc oxide right where it counts for a freshly weaned pig, without ever turning up as extra bodyweight.

Then there's the second lesson, and it's about dose. If more bacteria were simply better, the high dose should have won. It didn't. It was the low dose, a hundred times weaker, that produced the significantly higher daily gain in the later period, while both doses delivered the same benefits everywhere else⁴. A strain has a dose at which it works, tied to the specific effect you're after, and piling on CFU past that point buys you nothing reliable. A bigger number is not, by itself, a better product. It's a point worth remembering the next time a specification sheet leads with its CFU count.

Two uncertainties sit behind all of this, and I think an honest account should say so out loud. The first: what does a CFU count really mean for a spore former? A spore is dormant and inactive. To do anything, it first has to germinate into its working form, in enough numbers, in the right part of the gut. Viable spores at the point of feeding and active cells where they're actually needed are not the same thing, and the gap between the two is rarely quantified.

The second question follows on. Is a strain colonising the gut and holding a sustained effect, or simply passing through and nudging the ecosystem on its way out? For most commercial strains, the honest answer is that we don't fully know. And it matters, because a transient effect argues for continuous feeding across a phase rather than a short course.

So, are probiotics worth the inclusion? Dig into the research and the honest answer is: it depends. And the things it depends on are rarely the things printed on the front of the bag.

The pooled data is genuinely positive, but the effect is set by context. It's largest where the health challenge is highest, and it can shrink to almost nothing in a clean, high-performing unit already near its genetic ceiling. Genus and strain aren't details either. They're the active ingredient. And even the right strain only works within a specific dose range for a specific effect, which is exactly why a bigger CFU number is not the same as a better product.

A few things I'd keep in mind if you're putting probiotics in feed:

Using probiotics may improve gut health, which in turn can support performance. But look closely at the research and the link to growth stays inconsistent, which makes broad performance claims hard to justify. What is becoming clear, though, is that a well-chosen probiotic can support intestinal integrity, cut diarrhoea, and help hold pathogens like E. coli in check, in some trials to a degree that matches the tools it's meant to replace. And it's in exactly those situations, tackling a real health challenge, or filling the gap left by AGPs and therapeutic zinc oxide, that monogastric diets stand to gain the most from probiotic inclusion.